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It is a privilege for me to address you during 
this Seventh Annual Meeting of the American 
Venous Forum. As with other endeavors, the sev- 
enth in a series of days or annual meetings is an 
appropriate point for reflection on our organiza- 
tion's ability to have fulfilled its objectives. As stated 
in the Forum's bylaws, adopted February 23, 1989, 
during our first annual meeting, Article II-Objec- 
fives included the following: (1) to promote the 
study of or research in venous diseases; (2) to 
contribute to the active continuing education of its 
membership; (3) to hold annual meetings; and (4) 
to encourage the development and dissemination of
knowledge regarding venous disease. It is not sur- 
prising that an emphasis on research was the pri- 
mary objective in the minds of the founding mem- 
bers of this organization. Today, I want to focus 
on the topic of clinical research and review the 
opportunities provided by our organization through 
its annual program and administrative support of 
this objective. I contend that the American Venous 
Forum has gained great respect within the academic 
community of vascular surgery because of its com- 
mitment to clinical research. My opportunity to 
participate in this process as a founding member, 
program chairman, and recorder has constituted a 
rewarding experience, and I am honored to have 
served as your president during the past year. 
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DEFINING CLINICAL RESEARCH: ITS 
ORGANIZATION AND FUNDING 
Difficulties in defining clinical research have 
challenged colleagues in medicine and surgery 16 for 
the last 4 decades. A dichotomy between basic and 
clinical research has evolved and in some ways 
become a polarizing influence in our practices. As 
emphasized by Francis Moore I in his presidential 
address to the Society of University Surgeons in 
1958, "The surgical investigator must be a bridge- 
tender, channeling knowledge from biological sci- 
ence to the patient's bedside and back again. He 
traces his origin from both ends of the bridge. He is 
thus a bastard and is called this by everybody. Those 
at one end of the bridge say he is not a very good 
scientist, and those at the other say he does not spend 
enough time in the operating room. If  only he is 
willing to live with this abuse, he can continue to do 
his job effectively." However, it should be recognized 
that the surgical bridgetender is not only a demand- 
ing position, but one that carries with it more 
liabilities than the potentially more secure but 
perhaps limited life at either end of the bridge. In 
addition, the societal benefits derived from the 
bridgetender's conscientious pursuits are widely ac- 
knowledged as invaluable contributions to clinical 
practice. As further emphasized by Arnold Relmen 2
in his presidential address before the American 
Federation for Clinical Research in 1961, histori- 
cally, clinical research ad much of the flavor of the 
clinic about it, and it still was concerned with many 
things directly related to the "experience of the 
practicing physician." However, as the demands of 
basic research intruded on the classical clinical 
practice, some divergence inevitably occurred. Be- 
cause we have proceeded in headlong fashion toward 
more sophisticated basic research, it is occasionally 
easy to forget hat clinical research must be associated 
with clinical practice, if care of a basic clinical 
problem affecting the sick patient is to be influenced. 
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Table I. Clinical investigation 
Observational studies (hypothesis-seeking) 
Epidemiologic studies 
Cross-sectional studies 
Retrospective studies (case control) 
Prospective studies (cohort) 
Experimental studies (hypothesis-testing) 
Prospective studies (clinical trials) 
Uncontrolled studies 
Controlled studies 
Nonrandomized 
Randomized 
From Barnes RW. Understanding investigative clinical trials. 
J VAse SVRG 1989;9:609-18. 
Describing limits and responsibilities for clinical 
investigation i this new era continues to be an issue 
in modern practice. The term clinical research, how- 
ever, is derived from the Greek word "clincos," 
meaning at the bedside, a Although some authors 
would limit the definition of clinical research to 
precise questions regarding patient care, a broader 
definition defining a continuum from fundamental 
biomedical research through to clinical investigation 
has application to patient care. It is this relevance to 
patient care that is critical in defining clinical research 
and has broad implications for surgeons and mem- 
bers of the American Venous Forum. Under this 
definition, clinicians do not conform to a restrictive 
definition that would separate basic research from 
clinical investigation but rather apply the definition 
from the perspective of health care and disease. Our 
organization's current program is reflective of that 
commitment to clinical investigation. Clinical rel- 
evance is emphasized, and presentations can be 
categorized (Table I) as previously outlined by 
Barnes. 4Cross-sectional or prevalence studies exam- 
ine relationships between disease occurrence and 
other variables at one point in time. Retrospective 
studies are observational nd include individual and 
case series previously treated and compared with 
other groups. Prospective studies may be observa- 
tional and are defined as cohort studies or experi- 
mental depending on whether interventions are made 
to influence the course of the group's disease process. 
These experimental studies constitute the clinical 
trials, uncontrolled or controlled, and randomized or 
nonrandomized. Laboratory research is referred to as 
animal studies. Data (Fig. 1) from our program are 
compared with data from the national vascular 
societies 4 and emphasize our reliance on retrospective 
and cross-sectional analyses. However, cohort studies 
involving prospective analyses were used in a signif- 
icant manner by us, many suggesting future random- 
ized clinical trial assessments. It is the randomized 
clinical trial that represents the most rigorously 
controlled method to assess efficacy of new therapeu- 
tic choices. 6 Expanded use of this format is to be 
encouraged. 
Authors of abstracts and manuscripts from these 
programs, clinical investigators all, must also appre- 
ciate the environment within which our research 
activities are conducted. Incredible changes have 
occurred with regard to funding of clinical research. 
For example, the federal government's expenditure 
for research in 1940 was approximately $3 million, 
whereas the current research budget for the National 
Institutes of Health (NIH) has grown to an astound- 
ing $9 billion annually. It is obvious that clinical 
research as depended more and more on the federal 
government for its financial support during the last 
50 years. These activities are highly scrutinized by the 
public, which funds the N IH  with the expectation of
translating clinical research into meaningful contri- 
butions to the health care of the nation. As Schwartz 6 
has emphasized, "Congress is not spending 9 billion 
dollars per year, so that we can identify fundamental 
truths that might ultimately payoff. Now those of us 
who do research lmow that such fundamental re- 
search is central to the advancement of science, the 
advancement of biomedical research and the ad- 
vancement of clinical research. However, the rapid 
growth in the N IH  budget parallels the reframing of 
clinical research from mechanism-oriented to isease- 
oriented." 
Our challenge as clinical investigators in the 
American Venous Forum is to initiate and then main- 
tain an element of creditability with national funding 
organizations. At times, it is all too easy for the busy 
clinician to relinquish the responsibility for clinical 
investigation tohis colleagues in basic science. Under 
these circumstances the "two-platoon" system 2 of 
clinical investigation continues to be considered as a 
viable option by some. Clinical duties are conducted 
by the clinicians, whereas research is in the hands of 
the scientists. However, the essence of the modern 
clinical investigator is the prepared physician- 
scientist supported by innovative collaborative f- 
forts, generally with basic scientists colocated in his 
own institution or within the sphere of his clinical 
practice. My own interests in the physiology of the 
microcirculation have been enhanced greatly by my 
collaboration with investigators who possess insight 
into the scientific method and have been willing to 
associate themselves with me in a joint research effort 
designed to address problems of the sick patient- 
clinical relevancy. That collaboration also leads to an 
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Fig. 1. Data on types of clinical studies taken from programs of joint vascular societies for 
1970s (black bars) and 1980s Open bars) are compared with current program of the American 
Venous Forum, 1995 (gray bars) with its 73 plenary and poster presentations. CS represents 
cross-sectional; RET represents retrospective; COH represents cohort (prospective); UCT 
represents uncontrolled clinical trial; NCT represents nonrandomized controlled trial; RTG 
represents randomized controlled trial; LAB represents laboratory research. Modified from 
Barnes RW. Understanding investigative clinical trials. J VAsc Sue, G 1989;9:609-18. 
environment conducive for training of young physi- 
cians and surgeons. If we define appropriate clinical 
research for ourselves and colleagues in relationship 
to our responsibility for the care of the sick, we can 
then structure programs to involve our young associ- 
ates so that they may develop into the physician- 
scientists of the 1990s and the next century. As em- 
phasized by Francis Moore, 1 encouraging youth is 
the most important responsibility of senior investiga- 
tors. "Research born in the minds of young men [and 
women] is good research. It is appropriate research. 
It is living research." As Mal t  7 recently emphasized in
his editorial, practical surgeons doing basic research is
an essential component of clinical investigation. The 
formula for success by younger investigators elates 
to their opportunity to work with mentors in the field 
armed with appropriate scientific questions, funded 
by a peer review process that selects the very best 
projects, and in an environment of collaboration with 
basic science. Although the role of molecular biology 
has become preeminent in the 1980s and 1990s, 
Mal t  7 argues that there is no basic research for sur- 
geons. Rather the questions to be addressed by clini- 
cal research are relevant to the practice and the care of 
the sick patient. Members of the American Venous 
Forum have a unique opportunity to contribute clini- 
cally relevant questions to this process. Once the im- 
portant question is articulated, the prepared investi- 
gator uses the scientific method for generating an 
appropriate hypothesis, designing methods of re- 
search to address that question, analyzing results of 
experimentation, a d finally transferring the informa- 
tion to the scientific community via published ab- 
stracts and manuscripts. It is all too convenient to 
avoid this issue of conducting credible clinical re- 
search by deferring responsibility to the PhDs and 
MD-PhDs in a given department or school. Al- 
though a significant part of the fourfold increase in 
the number of NIH grant applications since 1970 has 
resulted because of PhD-initiated research, 3 new R01 
(individual initiated research) applications have com- 
parable success for funding regardless of the indi- 
vidual investigator's degree (MD, PhD, MD-PhD). 
We must not be discouraged by current funding of 
only 20% of these applications or the possibility of 
receiving the dreaded '~'~IH pink sheets" but should 
commit ourselves to pursuit of academic success rec- 
ognizing the value of our basic clinical inquiries. 
Funding for biomedical research as come from 
one of four traditional sources: (1) federal govern- 
ment (NIH, Veterans Affairs, other), (2) private 
industry, (3) philanthropy, and (4) clinical care 
reimbursement. Never before has so much funding 
been provided to such a large number of bright 
investigators in the history of medical research. This 
is based on the public's assumption that these 
expenditures will result in clinically significant con- 
tributions to the nation's health. Clearly this element 
of clinical relevance fuels the public's interest and 
support for our clinical research activities. Let us be 
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encouraged to participate in these endeavors. Al- 
though NIH funding can be an elusive goal, clini- 
cians have access to this and other sources, and we 
must exploit these opportunities. 
Research in venous diseases i a part of our basic 
and fundamental interest in vascular wall biology. 
• Obviously, arteries and veins are no longer consid- 
ered inactive conduits but are dynamic structures 
with complex biochemical functions and mecha- 
nisms. Endothelial cells are not mere semipermeable 
membranes. In a normal adult, the cells weigh only 
about 100 grams but occupy a surface area of more 
than 1000 m2. 8 In a complex interplay between 
endothelial cells within the vascular wall and circu- 
lating blood, a topic of Professor Coleridge Smith's 
presidential guest lecture, substances produced by the 
endothelium can modify blood flow. Conversely, 
abnormalities in the endothelium can result in the 
chemoattraction f cells that ultimately will result in 
tissue injury. White blood cell-mediated injury is a 
fascinating new chapter in the pathophysiology of
this age-old disease-venous stasis ulceration. We 
must encourage young physician-scientists who are 
interested in the pathophysiology of the vascular wall 
as it contributes to both arterial and venous disease. 
We must become more competitive for clinical 
research funding from the NIH or one of the other 
several sources. It is sobering news to learn from Dr. 
David Robinson, Director of the Vascular Research 
Program, Division of Heart and Vascular Diseases, 
National Heart, Lung and Blood Institute (NHLBI), 
NIH, that no recent funding of projects in venous 
disease has occurred (Robinson DM, in conversa- 
tion, 1995). Of course, research in vascular wall 
biology has been funded that will have important 
implications for venous disease; however, no specifi- 
cally designated venous disease topics have been 
funded. The topics reflected in our organization's 
annual program, however, must be considered in the 
future, when one reflects that chronic venous insuf- 
ficiency is the seventh leading cause of debilitating 
disease in the United States and that 10% to 35% of 
the U.S. adult population has some form of venous 
disorder, with more than 500,000 people diagnosed 
with venous stasis ulcers. 9 Combined with the 
current incidence of acute deep venous thrombosis 
and pulmonary embolism, the enormity of the 
clinical problem is staggering, and the number of sick 
patients who deserve clinically relevant research in an 
effort o improve their status mandates our enhanced 
contribution. There is no lack of important clinical 
questions in our arena, only a paucity of investigator- 
initiated grant applications in venous research! A 
note of encouragement, however, was sounded by 
Dr. Robinson. In the current reorganization of the 
NHLBI, equal status is given to the Heart and 
Vascular Disease Programs. He has suggested that a 
future goal for our organization might be the 
submission of appropriate topics for future study, a 
reasonable xtension of the original discussions 
between NHLBI and our organization. 
INITIATIVES IN RESEARCH 
Although the statement that research isa primary 
objective of the American Venous Forum is merito- 
rious, the objective becomes a hollow goal unless 
supported by our organization. One might ask, how 
can the Forum facilitate clinical research initiatives? I 
want to describe several past accomplishments that 
have prepared a basis for our organization's respon- 
sible pursuit of its first objective and suggest afuture 
agenda (Table II). From its inception in 1989, the 
Forum has offered a Residents' Research Prize 
Competition that has stimulated clinical research by 
surgical residents and fellows and continues at this 
meeting. This year's recipients, Drs. Caps and Rod- 
riguez, presented ata on important hemodynamic 
measurements in chronic venous insufficiency, and I 
congratulate them on their efforts. In 1992, the 
Forum appointed an Ad Hoc Committee on Socio- 
economic and Health Care Issues under the leader- 
ship of Dr. John Bergan, with Drs. Rich and 
DePalma as its members. Several visits to NHLBI, 
specifically the Cardiovascular Disease Committee, 
stimulated an interest in the funding of biomedical 
research in venous disease. In my opinion, this 
established a fertile environment for future options to 
be defined and developed by conscientious mentors 
assisted by younger colleagues. In 1993 the Executive 
Committee voted to establish an Ad Hoc Research 
Committee that followed the leadership example of 
the Lifeline Foundation Research Committee, an 
administrative innovation of Joint Council of The 
Society for Vascular Surgery and the North American 
Chapter of the International Society for Cardiovas- 
cular Surgery. I have appointed an exemplary group 
of young surgical investigators to our Research 
Committee, chaired by Dr. John Ricotta. Each of 
these individuals brings a special area of expertise to 
the development of investigator-initiated research: 
John J. Ricotta, MD-Acute  and chronic venous 
insufficiency; Thomas W. Wakefield, MD-Venous 
thrombosis and intimation: white cell-mediated 
injury; Kenneth Ouriel, MD-Venous  thrombosis: 
Pathophysiology, prevention, treatment; Michael C. 
Dalsing, MD-Animal  models and experiments o 
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evaluate management of venous insufficiency; Tho- 
mas G. Lynch, MD -- Diagnostic studies in venous 
disease. The committee has committed itself to the 
publication of a manuscript outlining suggested 
research topics to be used by members of this Forum 
and others as a resource document. The Research 
Committee will become astanding committee of the 
American Venous Forum this year, and anticipated 
terms of office have been defined as 5 years so that 
continuity can be assured. Furthermore, the chair- 
man of the committee has been nominated for a 
position on the Lifeline Research Committee of the 
Joint Council. Cooperative fforts and exchanges 
may therefore be encouraged. 
Optimal funding of clinical research in venous 
disease requires financial support for further training 
of bright young surgeon-scientists. The American 
Venous Forum has taken an initial step through 
negotiation of a research grant from the Jobst 
Foundation to establish a i-year research fellowship. 
Organized in 1994-1995 by Dr. Lazar Greenfield, 
past president of this Forum and current president of 
the American Venous Forum Foundation, the grant 
will support research efforts by a young surgical 
investigator in a basic science problem in venous 
disease. This year's recipient will study basic patho- 
physiologic mechanisms in the development of 
ulceration and chronic venous insufficiency by use of 
flow cytometry and other techniques in molecular 
biology. It is anticipated that projects of this type will 
stimulate our greater investigative efforts in the field 
of vascular wall biology and elucidate pathophysi- 
ologic mechanisms. The Jobst Award is symbolic of 
the Forum's commitment to clinical research. How- 
ever, the Forum needs other financial support from 
industry and philanthropic organizations to expand 
the number of available research fellowship oppor- 
tunities. In addition, senior members of this organi- 
zation need to apply for training grants as sponsored 
by the NHLBI and others to foster opportunities for 
surgical investigators during and after clinical resi- 
dency programs. The so-called '%series" awards are 
suitable. The new NHLBI Clinical Investigator 
Development Award incorporates features of two 
former programs, the Physician Scientist Award and 
the Clinical Investigator Award. Only by cultivating 
and nurturing our talent base can we hope to reap the 
benefits of scientific progress in the future. 1° 
The Vascular Fellowship rograms, approved by 
the Residency Review Committee in Surgery 
throughout he United States, constitute another 
resource for research training and are typically 
supported through clinical reimbursement funds. 
Table II. AVF clinical research initiatives: 
past and future recommendations 
* Resident's Research Prize Competition, 1989-present 
* Ad Hoc Committee on Socioeconomic and Health 
Care Issues, 1992-1993 (initial collaborative efforts 
with NHLBI) 
* Ad Hoc Committee on Research, 1993-1994 
Standing Committee on Research, 1995 
Publication of the committee's research goals, 1995 
• Iobst Research Fellowship Award, AVF Foundation, 
1995 
• Expanded Fellowship opportunities: other industrial 
sponsors, NHLBI training grants, 1995 
• Consensus meeting: Staff, Vascular Disease Program, 
NHLBI and AVF 
Executive and Research Committees to define topics in 
venous disease research, I995 
AVF, American Venous Forum. 
Many of the 2-year Fellowships incorporate 1 year of 
research activities into the 2-year training cycle. 
Mentors and trainees interested in clinical research 
prepare projects of merit for completion during that 
training year. In our program, our current clinical 
fellow, Dr. Pappas, completed a study on mono- 
nuclear cell function as associated with progressive 
phases of venous insufficiency. In the process, he has 
become proficient with flow cytometry, tissue culture 
techniques, and other methods in molecular biology. 
However, the demands of clinical practice in vascular 
surgery, such as inclusion of time for rotations 
through the noninvasive vascular laboratory or the 
endovascular interventional suite, have stimulated 
many program directors to reconsider this commit- 
ment o clinical research. I urge these directors, many 
of whom are in this audience, to use the research year 
for talented young surgeons who wish to pursue 
investigative questions of clinical relevancy. The 
successful application of this process is reflected in 
many of the Forum's presentations. 
Stimulated by the American Venous Forum's 
initiatives, enlightened collaboration of young inves- 
tigators and interested mentors in clinical research 
continues to offer the greatest opportunity for 
improved patient care. Our success will be as 
"bridgetenders" who successfully pursue relevant 
clinical research that can be translated into meaning- 
ful benefit for our patients. Opportunities are exciting 
and limited only by our imagination. To abandon the 
principles of clinical research by qualified committed 
clinicians is to become stagnant in a world of 
breathtaking scientific advance. Relman's admoni- 
tion more than 30 years ago continues to be 
applicable: "The goal of the clinical investigator may 
well be unattainable, but I feel convinced that the 
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attempt to achieve this elusive balance [basic and 
clinical] is what  constitutes the essence o f  clinical 
research." I add that "Hobson 's  choice ' 'n  o f  pursuing 
the goal o f  excellence in clinical research must  also be 
the essence o f  the American Venous Forum! 
REFERENCES 
1. Moore FD. The university in American surgery: presidential 
address, Society of University Surgeons. Surgery 1958;44:1- 
10. 
2. Relman AS. What is clinical research? Presidential address, 
American Federation for Clinical Research. Ctin Res 1961; 
3:516-8. 
3. Cadman EC. The new physician-scientist: a guide for the 
1990s. Clin Res 1990;38:191-8. 
4. Barnes RW. Understanding investigative clinical trials. J VASe 
SuRO 1989;9:609-18. 
5. Schwartz JS, Presidential remarks-towards a redefinition of 
cfinical research. American Federation for Clinical Research. 
Clin Res 1992;40:64t-4. 
6. Hobson RW. Randomized clinical trials: what can we expect? 
J VAsc SURG !991;13:539-43. 
7. Malt RA. Surgeons doing basic research [Editorial]. Surgery 
1991;109:563-5. 
8. Falkow B, Neil E. Circulation. New York: Oxford University 
Press, 1971. 
9. White GH. Chronic venous insufficiency. Chapter (pp 865- 
88) In: Veith FI, Hobson RW, Williams RA, Wilson SE, eds. 
Vascular surgery: principles and practice. 2nd ed. New York: 
McGraw-Hill, 1993. 
10. Lcnfant C. NHLBI research training and career development 
programs, Circulation 1994;89:1-2. 
i1. Greenfield LJ. Presidential ddress: crossroads, the American 
Venous Forum. ~ VASe Suac 1991;14:573-5. 
Submitted March 17, 1995; accepted March 28, 1995. 
BOUND VOLUMES AVAILABLE TO SUBSCRIBERS 
Bound volumes of the JOURNAL OF VASCULAR SURGERY for 1995 are available to sub- 
scribers only. They may be purchased from the publisher at a cost of $84.00 for domestic, $109.14 
for Canadian, and $102.00 for international subscribers for Vol. 21 (January to June) and Vol. 
22 (July to December). Price includes hipping charges. Each bound volume contains a subject 
and author index, and all advertising is removed. Copies are shipped within 60 days after 
publication of the last issue in the volume. The binding is durable buckram with the journal name, 
volume number, and year stamped in gold on the spine. Payment must accompany all orders. 
Contact Subscription Services, Mosby-Year Book, Inc., 11830 Westline Industrial Dr., St. Louis, 
MO 63146-3318, USA. In the United States call toll free (800)325-4177, ext. 4351. In Missouri 
or foreign countries call (314)453-4351. 
Subscriptions must be in force to qualify. Bound volumes are not available in place of a 
regular JOURNAL subscription. 
